Guidelines for Authors
www.karger.com/neurodis_guidelines
 Introduction
Submission
Modeling Neurodegenerative Diseases in vivo
Conditions
Arrangement
Color Illustrations
References
Digital Object Identifier (DOI)
Drugs
Abbreviations
Author's ChoiceTM, NIH-Funded Research, Self-Archiving
Proofs
Reprints
Introduction
Neurodegenerative Diseases is a bimonthly, multidisciplinary journal for the publication of advances in the understanding of neurodegenerative diseases, including Alzheimer disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington disease and related neurological and psychiatric disorders. Neurodegenerative Diseases publishes results from basic and clinical scientific research programs designed to better understand the normal functions of genes and proteins involved in neurodegenerative diseases, to characterize their role in pathogenic disease mechanisms, to model their functions in animals and to explore their roles in the diagnosis, treatment and prevention of neurodegenerative diseases. It is our firm belief that successful strategies for novel treatments of neurodegenerative diseases will emerge from the intelligent integration of basic neurobiology with clinical sciences. Therefore, Neurodegenerative Diseases will accept high-quality papers from a broad spectrum of scientific research areas ranging from molecular and cell biology to neuroscience, pharmacology, genetics and the clinical sciences.
Neurodegenerative Diseases is a peer-reviewed journal that publishes original research in the form of Articles and Brief Communications to Neurodegenerative Diseases as well as Review Articles, Minireviews and Commentaries.
Submission
Only original papers written in English are considered and should be submitted online:
Should you experience any problems with your submission, please contact:
ndd@karger.ch
Editorial Office 'Neurodegenerative Diseases'
S. Karger AG
P.O. Box
CH-4009 Basel (Switzerland)
Tel. +41 61 306 1358
Fax +41 61 306 1434
Articles should be fully documented reports of original research. They must describe significant and original observations to be critically evaluated and, if necessary, repeated. They do not normally exceed 6 printed pages including all figures, tables and references.
Brief Communications to Neurodegenerative Diseases are short reports of original research and are intended to provide a rapid means of reporting new findings of sufficient importance. They do not normally exceed 2 printed pages including an abstract, essential references and not more than 3 tables or figures.
Review Articles, Minireviews and Commentaries are either invited by the Editors or may be submitted for consideration. Authors who wish to contribute a manuscript to one of these categories should contact the Editor-in-Chief.
Review Articles describe new developments of interdisciplinary significance and highlight unresolved questions and future directions. They do not generally occupy more than 9 printed pages.
Minireviews should focus on topics of current interest and not exceed 5 printed pages.
Commentaries should offer a more personalized perspective on a topic that will be of interest to the general readership and fill an integral number of printed pages, generally one or two, including one or two small figures. All contributions to these categories will be subjected to editorial review.
Reports should comprise title page, Key Words, Abstract, Introduction, Results and Discussion, References, tables, figure legends, and figures – in this order.
Modeling Neurodegenerative Diseases in vivo
Editorial policies and guidelines for submission to this section are as those given for the prime section of ‘Neurodegenerative Diseases’, except that the editorial responsibility falls within the province of the section editors Jean-Philippe Loeffler and José-Luis Gonzalez de Aguilar, Strasbourg. Contributions should be submitted online:
www.karger.com/ndd
Please mention in your convering letter that your article is submitted for publication in ‘Modeling Neurodegenerative Diseases in vivo’.
Conditions
Only manuscripts that conform to the Guidelines for Authors will be considered and are subject to editorial review.
The manuscript must be accompanied by a cover letter stating that all authors have seen and given their approval for submission of the manuscript to be considered for publication in Neurodegenerative Diseases. Manuscripts are accepted for review with the understanding that persons cited in unpublished work have approved such citations. Authors may provide the names and contact information for three or four suggested reviewers for their papers.
Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication or have not already been published elsewhere. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of Neurodegenerative Diseases and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.
The authors agree that their articles will be accompanied, if necessary, by a simplified version written by a scientific writer.
Manuscripts that do not comply with the ethical standards recommended by the Helsinki Declaration will not be accepted.
Arrangement
Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.
NB: Authors wishing to preserve the phonetic meaning of diacritics (PubMed reduces diacritics to their root characters) must spell their names accordingly when submitting manuscripts (e.g. Müller should be Mueller).
Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone/fax numbers and e-mail address.
Key words: For indexing purposes, a list of 3–10 key words (no abbreviations) in English is needed.
Abstract: Each paper needs an abstract of about 200 words, and should be structured as follows:
Background: What prompted the study?
Objective: What is the purpose of the study?
Methods: How was the study carried out?
Results: What are the most important findings?
Conclusion: What is the most important conclusion?
The abstract should not exceed 250 words, and any abbreviations must be explained.
Footnotes: Avoid footnotes. When essential, they should be numbered consecutively and typed at the foot of the appropriate page.
Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be prepared on separate sheets. Tables require a heading and figure legends should be supplied on a separate sheet. For the reproduction of illustrations, only good drawings and original photographs will be accepted; negatives or photocopies cannot be used. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm) or provide crop marks. On the back of each illustration, indicate its number, the author’s name, and ‘top’ with a soft pencil. Electronically submitted b/w half-tone and color illustrations must have a final resolution of 300 dpi after scaling, and line drawings one of 800–1,200 dpi.
Color Illustrations
Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.
Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 760.00.
References
Identify references in the text with Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surnames of the authors followed by their initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. (Also see International Committee of Medical Journal Editors: Uniform requirements for manuscripts submitted to biomedical journals. N Engl J Med 1997;336:309–315. www.icmje.org)
|
Examples
(a) Papers published in periodicals:
Desai MY, De la Peña-Almaguer E, Mannting F: Abnormal heart rate recovery after exercise: A comparison with known indicators of increased mortality. Cardiology 2001;96:38–44.
Hadler, W.A., S.R. Silveira (1981) Técnica histoquímica que permite iscriminar o colesterol de substâncias afins e de seus ésteres. Cienc Cult 33(suppl): 586–587.
(b) Papers published only with DOI numbers:
Theoharides TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol DOI: 10.1159/000063858.
(c) Books:
Matheis G, Moritz A, Scholz M (eds): Leukocyte Depletion in Cardiac Surgery and Cardiology. Basel, Karger, 2002.
(d) Edited books:
Gladish GW, Haponik EF: Virtual Bronchoscopy; in Bolliger CT, Mathur PM (eds): Interventional Bronchoscopy. Prog Respir Res. Basel, Karger, 2000, vol 30, pp 253–266.
|
Papers that have been submitted but are not yet accepted should not be listed in the bibliography, but can be referred to in the text as unpublished observations. If details of methods are only available in papers that are ‘in press’, copies of the papers should be included with the manuscript submitted to Neurodegenerative Diseases so that the editorial referees can have adequate information to judge the manuscript.
Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.
Digital Object Identifier (DOI)
S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org
Drugs
Generic names should be used in text, tables, and figures. Trade names in upper case may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. The chemical nature of new drugs must be given when known.
Abbreviations
When an abbreviation is used in the manuscript, it should be defined in the text the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs/chemicals may be used if properly defined with the chemical or generic name when the abbreviation is first used. Excessive use of abbreviations in the text, however, is strongly discouraged. Most abbreviations are used without punctuation, with no distinction between singular and plural forms.
Author's ChoiceTM
Karger's Author's ChoiceTM service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.Karger.com. The option is available for a one-time fee of CHF 2,750.00, which is a permissible cost in grant allocation. More information can be found at www.karger.com/authors_choice.
NIH-Funded Research
The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author's ChoiceTM service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH's Public Access Policy is available here.
Self-Archiving
Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution's servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher's version, and must acknowledge the publisher's copyright. Authors selecting Karger's Author's ChoiceTM feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.
Proofs
Unless otherwise indicated, proofs are sent to the first-named author and should be returned with the least possible delay. Alterations made in proofs, other than the correction of printer’s errors, are charged to the author. No page proofs are supplied.
Reprints
Order forms and a price list will be sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.
|
|
|
| Search in this journal
|
|
|
|
|
Now listed in MEDLINE/PubMed!
|
For non-native English speakers and international authors who would like assistance with their writing before submission, we suggest American Journal Experts for their scientific editing service. |
|
|
Online Manuscript Submission
Guidelines
